Bausch + Lomb appoints four new directors, reaffirms 2026 guidance after Q2 revenue of $1.394B

Bausch & Lomb Corp

Q2 revenue $1.394B, up 9% reported and 8% constant currency vs Q2 2025; broad-based double-digit growth in Surgical and Pharma.
Cash flow from operations rose to $153M in Q2 from $32M in Q1; adjusted cash flow from operations $161M.
Full-year 2026 guidance reaffirmed: revenue $5.44B–$5.54B, Adj EBITDA (ex-IPR&D) $1.025B–$1.075B.
Board adds Thomas Appio (CEO of Bausch Health), Robert Chersi, Laurence Paul, and Barbara Trebbi; four prior directors resigned.
Resignations not due to disagreement; departing directors receive prorated cash and full RSU vesting; Thomas Ross gets $400K consulting fee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.